PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2018

AMPK/PGC1alpha activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis.

Mouse / Chemical/toxin

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 30172748 ↗2018Reported benefit

AMPK/PGC1alpha activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis.

MouseChemical/toxinC57BL/6Male

Model: Acute doxorubicin induced cardiotoxicity, doxorubicin 20 mg/kg cumulative dose in vivo and 1 micromolar doxorubicin in H9c2 cells

Melatonin markedly alleviated doxorubicin-induced acute cardiac dysfunction and myocardial injury, inhibited mitochondrial dysfunction and morphological disorder, apoptosis and oxidative stress, through AMPK activation and PGC1alpha upregulation. These effects were reversed by AMPK or PGC1alpha siR…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.